Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: April 11, 2025
Reporting Period: Event-based report for April 11, 2025
This filing reports a specific corporate event under Item 8.01 (Other Events) regarding the expansion of a clinical trial. It does not contain periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a clinical trial milestone and does not include financial statements or performance metrics.
Material Changes
Clinical Trial Expansion: On April 11, 2025, BioCardia announced that Emory University School of Medicine in Atlanta, Georgia, has begun enrolling patients with ischemic heart failure into the Company's ongoing pivotal Phase III CardiAMP HF II trial.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the strategic progress of the Phase III CardiAMP HF II trial by adding a new enrollment site at a major academic medical center.
Legal Disclaimer: The information in Item 8.01 and the attached press release (Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial protocols.
- Confirm the total number of enrollment sites currently active in the CardiAMP HF II trial.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor future 8-K filings for additional site activations or interim data readouts from the Phase III trial.